Header
For Healthcare Professionals
SPEVIGO® Logo
Spevigo-Home-banner
IN ADULT PATIENTS WITH GENERALIZED PUSTULAR PSORIASIS (GPP)

Control the danger of GPP flares like never before1-4

SPEVIGO® is the first EMA-approved treatment for GPP flares. With SPEVIGO®, 54.3% of patients achieved complete pustular clearance* at Week 1.1,4

MOA
Card_1_MOA

The only treatment to block the key inflammatory pathway in GPP by targeting the IL-36 receptor1,4,5

MOA
Efficacy
Efficacy Chart

With SPEVIGO®, 54.3% of patients achieved complete pustular clearance* at Week 11,4

Efficacy

*Pustular clearance defined as GPPGA pustulation subscore of 0 (no visible pustules).1

EMA=European Medicines Agency; GPPGA=Generalized Pustular Psoriasis Physician Global Assessment; IL-36=interleukin-36; MOA=mechanism of action.

References

  1. SPEVIGO® Summary of Product Characteristics. Boehringer Ingelheim Pharmaceuticals, Inc; 2022.

  2. Gooderham MJ, Van Voorhees AS, Lebwohl MG. An update on generalized pustular psoriasis. Expert Rev Clin Immunol. 2019;15(9):907-919. doi:10.1080/1744666X.2019.1648209

  3. Ly K, Beck KM, Smith MP, Thibodeaux Q, Bhutani T. Diagnosis and screening of patients with generalized pustular psoriasis. Psoriasis (Auckl). 2019;9:37-42. doi:10.2147/PTT.S181808

  4. Bachelez H, Choon SE, Marrakchi S, et al; for the Effisayil 1 Trial Investigators. Trial of spesolimab for generalized pustular psoriasis. N Engl J Med. 2021;385(26):2431-2440. doi:10.1056/NEJMoa2111563

  5. Johnston A, Xing X, Wolterink L, et al. IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis. J Allergy Clin Immunol. 2017;140(1):109-120. doi:10.1016/j.jaci.2016.08.056